For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer.
Keywords: bladder cancer; metastasectomy; oligometastases; prostate cancer; radiotherapy; renal cancer; urological tumours.
© the authors; licensee ecancermedicalscience.